ID

28582

Descrizione

Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropathy; ODM derived from: https://clinicaltrials.gov/show/NCT00832572

collegamento

https://clinicaltrials.gov/show/NCT00832572

Keywords

versioni (1)
  1. 23/01/18 23/01/18 -
Titolare del copyright

See clinicaltrials.gov

Caricato su

23 gennaio 2018

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Coronary Artery Disease NCT00832572

Inglese

Eligibility Coronary Artery Disease NCT00832572

1 moduli  
Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
males or females aged ≥ 18 years
Descrizione

Age

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0001779
coronary artery disease with a clinically diagnosed peripheral neuropathy
Descrizione

Coronary Artery Disease | Peripheral Neuropathy

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1956346
UMLS CUI [2]
C0031117
willing and able to provide signed informed consent and health insurance portability and accountability act (hipaa) authorization
Descrizione

Informed Consent

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0021430
willing and able to comply with the requirements of the protocol and follow directions from the clinic staff
Descrizione

Protocol Compliance

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0525058
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
history of allergy or intolerance to ranolazine
Descrizione

Hypersensitivity Ranolazine | Intolerance to Ranolazine

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0073633
UMLS CUI [2,1]
C1744706
UMLS CUI [2,2]
C0073633
any condition or concomitant medication that would have precluded the safe use of ranolazine as outlined in the prescribing information sheet (see appendix e)
Descrizione

Condition Excludes Ranolazine | Pharmaceutical Preparations Exclude Ranolazine

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0348080
UMLS CUI [1,2]
C0332196
UMLS CUI [1,3]
C0073633
UMLS CUI [2,1]
C0013227
UMLS CUI [2,2]
C0332196
UMLS CUI [2,3]
C0073633
in the judgment of the investigator, any clinically-significant ongoing medical condition that might jeopardize the patient's safety or interfere with the absorption, distribution, metabolism or excretion of the study drug
Descrizione

Medical condition compromises Patient safety | Medical condition Interferes with Absorption Investigational New Drugs | Medical condition Interferes with Distribution Investigational New Drugs | Medical condition Interferes with Metabolism Investigational New Drugs | Medical condition Interferes with Excretion Investigational New Drugs

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C3843040
UMLS CUI [1,2]
C2945640
UMLS CUI [1,3]
C1113679
UMLS CUI [2,1]
C3843040
UMLS CUI [2,2]
C0521102
UMLS CUI [2,3]
C0237442
UMLS CUI [2,4]
C0013230
UMLS CUI [3,1]
C3843040
UMLS CUI [3,2]
C0521102
UMLS CUI [3,3]
C1378698
UMLS CUI [3,4]
C0013230
UMLS CUI [4,1]
C3843040
UMLS CUI [4,2]
C0521102
UMLS CUI [4,3]
C0025519
UMLS CUI [4,4]
C0013230
UMLS CUI [5,1]
C3843040
UMLS CUI [5,2]
C0521102
UMLS CUI [5,3]
C0221102
UMLS CUI [5,4]
C0013230
in the judgment of the investigator, clinically-significant abnormal physical findings during screening (excluding the patient's peripheral neuropathy condition)
Descrizione

ABNORMAL PHYSICAL FINDING | Exception Peripheral Neuropathy

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0149610
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0031117
use of any experimental or investigational drug or device within 30 days prior to screening
Descrizione

Investigational New Drugs | Investigational Medical Device

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0013230
UMLS CUI [2]
C2346570
pregnant or breast feeding, or (if premenopausal), not practicing an acceptable method of birth control (as detailed in inclusion criterion 4)
Descrizione

Pregnancy | Breast Feeding | Premenopausal state Contraceptive methods Absent

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
UMLS CUI [3,1]
C0232969
UMLS CUI [3,2]
C0700589
UMLS CUI [3,3]
C0332197
had received prior treatment with, or investigational exposure to, ranolazine within 7 days prior to randomization
Descrizione

Ranolazine Prior Therapy | Exposure to Ranolazine

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0073633
UMLS CUI [1,2]
C1514463
UMLS CUI [2,1]
C0332157
UMLS CUI [2,2]
C0073633
clinically significant hepatic impairment
Descrizione

Hepatic impairment

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0948807
had end-stage renal disease requiring dialysis
Descrizione

End stage renal disease Requirement Dialysis

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0022661
UMLS CUI [1,2]
C1514873
UMLS CUI [1,3]
C0011946
psychological or addictive disorders (not limited to, but including drug and/or alcohol dependency) that may have precluded patient consent or compliance, or that may have confounded study interpretation
Descrizione

Mental disorders Exclude Informed Consent | Addictive Behavior Excludes Informed Consent | Mental disorders Exclude Compliance behavior | Addictive Behavior Excludes Compliance behavior | Mental disorder Interferes with Interpretation Study data | Addictive Behavior Interferes with Interpretation Study data | Substance Dependence

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0004936
UMLS CUI [1,2]
C0332196
UMLS CUI [1,3]
C0021430
UMLS CUI [2,1]
C0085281
UMLS CUI [2,2]
C0332196
UMLS CUI [2,3]
C0021430
UMLS CUI [3,1]
C0004936
UMLS CUI [3,2]
C0332196
UMLS CUI [3,3]
C1321605
UMLS CUI [4,1]
C0085281
UMLS CUI [4,2]
C0332196
UMLS CUI [4,3]
C1321605
UMLS CUI [5,1]
C0004936
UMLS CUI [5,2]
C0521102
UMLS CUI [5,3]
C0459471
UMLS CUI [5,4]
C0681873
UMLS CUI [6,1]
C0085281
UMLS CUI [6,2]
C0521102
UMLS CUI [6,3]
C0459471
UMLS CUI [6,4]
C0681873
UMLS CUI [7]
C0038580
positive pregnancy test at baseline (pre-randomization, day 0)
Descrizione

Pregnancy test positive

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0240802
Ritorna all'inizio della pagina

Similar models

Eligibility Coronary Artery Disease NCT00832572

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
males or females aged ≥ 18 years
boolean
C0001779 (UMLS CUI [1])
Coronary Artery Disease | Peripheral Neuropathy
Item
coronary artery disease with a clinically diagnosed peripheral neuropathy
boolean
C1956346 (UMLS CUI [1])
C0031117 (UMLS CUI [2])
Informed Consent
Item
willing and able to provide signed informed consent and health insurance portability and accountability act (hipaa) authorization
boolean
C0021430 (UMLS CUI [1])
Protocol Compliance
Item
willing and able to comply with the requirements of the protocol and follow directions from the clinic staff
boolean
C0525058 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Hypersensitivity Ranolazine | Intolerance to Ranolazine
Item
history of allergy or intolerance to ranolazine
boolean
C0020517 (UMLS CUI [1,1])
C0073633 (UMLS CUI [1,2])
C1744706 (UMLS CUI [2,1])
C0073633 (UMLS CUI [2,2])
Condition Excludes Ranolazine | Pharmaceutical Preparations Exclude Ranolazine
Item
any condition or concomitant medication that would have precluded the safe use of ranolazine as outlined in the prescribing information sheet (see appendix e)
boolean
C0348080 (UMLS CUI [1,1])
C0332196 (UMLS CUI [1,2])
C0073633 (UMLS CUI [1,3])
C0013227 (UMLS CUI [2,1])
C0332196 (UMLS CUI [2,2])
C0073633 (UMLS CUI [2,3])
Medical condition compromises Patient safety | Medical condition Interferes with Absorption Investigational New Drugs | Medical condition Interferes with Distribution Investigational New Drugs | Medical condition Interferes with Metabolism Investigational New Drugs | Medical condition Interferes with Excretion Investigational New Drugs
Item
in the judgment of the investigator, any clinically-significant ongoing medical condition that might jeopardize the patient's safety or interfere with the absorption, distribution, metabolism or excretion of the study drug
boolean
C3843040 (UMLS CUI [1,1])
C2945640 (UMLS CUI [1,2])
C1113679 (UMLS CUI [1,3])
C3843040 (UMLS CUI [2,1])
C0521102 (UMLS CUI [2,2])
C0237442 (UMLS CUI [2,3])
C0013230 (UMLS CUI [2,4])
C3843040 (UMLS CUI [3,1])
C0521102 (UMLS CUI [3,2])
C1378698 (UMLS CUI [3,3])
C0013230 (UMLS CUI [3,4])
C3843040 (UMLS CUI [4,1])
C0521102 (UMLS CUI [4,2])
C0025519 (UMLS CUI [4,3])
C0013230 (UMLS CUI [4,4])
C3843040 (UMLS CUI [5,1])
C0521102 (UMLS CUI [5,2])
C0221102 (UMLS CUI [5,3])
C0013230 (UMLS CUI [5,4])
ABNORMAL PHYSICAL FINDING | Exception Peripheral Neuropathy
Item
in the judgment of the investigator, clinically-significant abnormal physical findings during screening (excluding the patient's peripheral neuropathy condition)
boolean
C0149610 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0031117 (UMLS CUI [2,2])
Investigational New Drugs | Investigational Medical Device
Item
use of any experimental or investigational drug or device within 30 days prior to screening
boolean
C0013230 (UMLS CUI [1])
C2346570 (UMLS CUI [2])
Pregnancy | Breast Feeding | Premenopausal state Contraceptive methods Absent
Item
pregnant or breast feeding, or (if premenopausal), not practicing an acceptable method of birth control (as detailed in inclusion criterion 4)
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0232969 (UMLS CUI [3,1])
C0700589 (UMLS CUI [3,2])
C0332197 (UMLS CUI [3,3])
Ranolazine Prior Therapy | Exposure to Ranolazine
Item
had received prior treatment with, or investigational exposure to, ranolazine within 7 days prior to randomization
boolean
C0073633 (UMLS CUI [1,1])
C1514463 (UMLS CUI [1,2])
C0332157 (UMLS CUI [2,1])
C0073633 (UMLS CUI [2,2])
Hepatic impairment
Item
clinically significant hepatic impairment
boolean
C0948807 (UMLS CUI [1])
End stage renal disease Requirement Dialysis
Item
had end-stage renal disease requiring dialysis
boolean
C0022661 (UMLS CUI [1,1])
C1514873 (UMLS CUI [1,2])
C0011946 (UMLS CUI [1,3])
Mental disorders Exclude Informed Consent | Addictive Behavior Excludes Informed Consent | Mental disorders Exclude Compliance behavior | Addictive Behavior Excludes Compliance behavior | Mental disorder Interferes with Interpretation Study data | Addictive Behavior Interferes with Interpretation Study data | Substance Dependence
Item
psychological or addictive disorders (not limited to, but including drug and/or alcohol dependency) that may have precluded patient consent or compliance, or that may have confounded study interpretation
boolean
C0004936 (UMLS CUI [1,1])
C0332196 (UMLS CUI [1,2])
C0021430 (UMLS CUI [1,3])
C0085281 (UMLS CUI [2,1])
C0332196 (UMLS CUI [2,2])
C0021430 (UMLS CUI [2,3])
C0004936 (UMLS CUI [3,1])
C0332196 (UMLS CUI [3,2])
C1321605 (UMLS CUI [3,3])
C0085281 (UMLS CUI [4,1])
C0332196 (UMLS CUI [4,2])
C1321605 (UMLS CUI [4,3])
C0004936 (UMLS CUI [5,1])
C0521102 (UMLS CUI [5,2])
C0459471 (UMLS CUI [5,3])
C0681873 (UMLS CUI [5,4])
C0085281 (UMLS CUI [6,1])
C0521102 (UMLS CUI [6,2])
C0459471 (UMLS CUI [6,3])
C0681873 (UMLS CUI [6,4])
C0038580 (UMLS CUI [7])
Pregnancy test positive
Item
positive pregnancy test at baseline (pre-randomization, day 0)
boolean
C0240802 (UMLS CUI [1])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial